PIK3CA in metastatic breast cancer
The Phosphoinositide 3-kinase (PI3K) pathway is one of the most frequently altered pathways in human cancer1. PIK3CA is a gene that encodes a subunit of the PI3K protein, and mutant PIK3CA has been implicated in the pathogenesis of several cancers, including HR+, HER2- metastatic breast cancer.
Testing for clinically relevant biomarkers, such as PIK3CA, using standardized workflows can help clinicians and patients make informed treatment decisions.
The therascreen PIK3CA RGQ PCR Kit is a clinically validated companion diagnostic (CDx) test to identify breast cancer patients that may be eligible for treatment with the ∝-selective PI3K-inhibitor PIQRAY (alpelisib), based on the detection of a PIK3CA mutation.